Research
Hormonal
Insulin resistance is a major cardiovascular risk factor in subjects without diabetes and serves as a key link between MAFLD/NASH and cardiovascular disease.
Even if you do not have diabetes, insulin resistance associated with fatty liver disease significantly increases your risk of heart disease. Addressing insulin sensitivity through lifestyle changes is crucial for cardiovascular health, regardless of your diabetes status.
GoodSupportsHIGH confidence
MAFLD is strongly associated with insulin resistance, which is involved in its pathogenesis and progression to NASH. Insulin resistance is a major cardiovascular risk factor in subjects without diabetes. However, T2D has been considered the most common link between MAFLD/NASH and CVD.
Why this rating
Well-established in literature and cited in the review.
Source
Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases
Jorge Gutiérrez‐Cuevas et al. · International Journal of Molecular Sciences · 2021
DOI 10.3390/ijms222111629
narrative_reviewCited 201×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity-induced adipose tissue dysfunction and systemic insulin resistance drive the development of MAFLD/NASH, which in turn exacerbates cardiovascular disease risk through the release of pro-atherogenic, pro-coagulant, and pro-inflammatory mediators from the liver.Good
- Obesity causes structural and functional cardiac alterations, including left ventricular hypertrophy, diastolic dysfunction, and atrial fibrillation, primarily through increased blood volume, cardiac output, and neuro-hormonal activation (RAAS).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →